Appreciate the⚠️caution voiced by #PCWG4@AarmstrongDuke et al.@JCO_ASCO#PSMA imaging in #ProstateCancer is not🚫ready for prime time to determine treatment failure (distinct from imaging PD) in clinical practice
PSMA may harm pts if it leads to stopping a tx too quickly
The @thenci past meets the present @asco#GU26
Dr. Melissa Abel @melissaabel20 discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh @harpreet_md
The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time @theNCI
As we get ready for the update on the overall survival in #BRCAAway trial @asco#GU26
It is worth noting the small number of patients that’s crossed over.
In that context this data has its limits in comparing combination vs sequence in #ProstateCancer
@AmarUKishan POSEIDON meta-analysis of 6 PhIII RCTs on hormonal therapy (HT) after post-op RT (PORT) in localized #Prostatecancer ➡️ no OS benefit w/HT to PORT & no significant interaction b/t duration of HT & this effect (p-interaction 0.25) for PSA<0.5
#GU26@OncoAlert
#BRCAaway OS data presented by Dr. Maha Hussein
#GU26@asco
Launched prior to large phase 3s in #ProstateCancer Cancer
Provocative data but as Dr Hussein acknowledges small numbers in cross over (8 patients) limits ability to truly understand sequencing vs combo
Dr Evan Yu takes stage @asco#GU26 to discuss #Peace3 & #BRCAaway
Too often superlatives are thrown around on this app…
But do yourself a favor. Watch this whole discussion. One of the more thoughtful takes on modern clinical trial dilemmas in #ProstateCancer
Thank you Dr Yu
It’s always a beautiful day when you can go to clinic and observe a successful #bicalutamide withdrawal maneuver
📉
Yes… even in 2025 🙂
Sometimes less is more in #ProstateCancer (#nmCRPC)
Flashback to Dr. Evan Yu & colleagues…
https://t.co/DjuJ6NfR9h
What did I learn at #ASCO2025 ?
1. Increasing intensity of treatment improves PFS& toxicity- still need OS data for shared decision making
2. Powerful new treatments for #ProstateCancer are coming. get patients on trial
3. Get biomarkers on your #ProstateCancer
Thanks everyone!
As new #mCSPC#PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs
Did we lower standard to PFS when both agents are approved for mCRPC?
🤔
#ProstateCancer#ASCO25
https://t.co/QOdBqMuBYC